Details - Clinical Research

Clinical Research Details

Back to List

Descriptive Information

Title

RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors

Investigator Name

Arafat Tfayli

at35@aub.edu.lb

Protocol Id

17852

Status

Recruiting

Study Type

Observational A clinical study in which participants identified as belonging to study groups are assessed for biomedical or health outcomes. Participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to specific interventions (as in an interventional study).

Phase

Looking for Med Students Volunteers

Sponsors

Bayer

Conditions and Keywords

Conditions

thyroid cancer

Keywords

thyroid cancer,multikinase inhibitors

Study Design

Eligibility and IRB

Gender

Both

Age Limits

Min: 18

Max:

IRB Approval

Yes

Healthy Volunteer

Study Description

The purpose of the study is to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.

Population Description

Sampling Method

Inclusion Criteria

Inclusion Criteria:

Histologically/cytologically documented DTC (papillary, follicular, Hurthle cell, and poorly differentiated carcinoma)
DTC refractory to RAI
Radiological progression and preferably according to RECIST 1.1
No symptoms due to DTC
>/=1cm diameter of lesion confirmed by radiological exam
Life expectancy of at least 6 months

Exclusion Criteria

Exclusion Criteria:

Plan to be treated according to a clinical trial protocol for intervention including a locoregional therapy or systemic therapy
Previous treatment with MKIs for advanced disease
Hospice patients

Back to List